Navigation Links
Seahorse Bioscience Receives Poster Award from the European Association for the Study of Obesity
Date:7/18/2008

Mechanism of Action of Metformin on Insulin Sensitization Poster Wins One

of Three Prizes

N. BILLERICA, Mass., July 18 /PRNewswire/ -- Seahorse Bioscience, Inc., leaders in real-time measurement of cellular bioenergetics announced today the receipt of The European Association for the Study of Obesity (EASO) poster award at the 16th European Congress on Obesity (ECO 2008) May 14-17, 2008 in Geneva, Switzerland.

The poster, Mechanism of Action of Metformin on Insulin Sensitization: Selective Fatty Acid Oxidation (FAO) over Glucose Oxidation via Inhibition of Complex I and Activation of AMP-activated protein kinase in C2C12 myocytes presented by author Dr. Min Wu of Seahorse Bioscience, was one of three posters to win the prestigious 2008 EASO Poster Prize. Poster Prize winners have already been listed on the EASO website (http://www.easoobesity.org) and will be highlighted in the Association's next e-newsletter.

"We are very pleased that EASO recognized our work on cellular mechanism of action of metformin," said David Ferrick, Vice President of Biology. "It is the bioenergetic analysis of fuel substrate selections that revealed the mechanism of action in different cell types, an analysis with the potential to be very powerful in the understanding and treatment of many other age-related diseases."

"It is unusual for an instrument manufacturer to be recognized for scientific contribution but Seahorse XF technology enables novel discoveries by bringing to light the importance of energy producing pathways of the cell," said Steven Chomicz, Vice President of Sales and Marketing for Seahorse Bioscience. "Dr. Wu used the features of the XF24 extracellular flux analyzer to perform an eloquent experiment which revealed metformin's, heretofore, unknown mechanism of action. This potential for award winning discoveries is why Seahorse XF technology is used by leading bioenergetic labs worldwide."

About Seahorse Bioscience, Inc.

Seahorse Bioscience is changing cancer, obesity, diabetes and age-related drug discovery programs the world over. Seahorse headquarters are located in North Billerica, Massachusetts. For more information, please visit http://www.seahorsebio.com.

If you would like more information about Seahorse Bioscience, Inc., or would like to schedule a meeting with Steve Chomicz, please contact Kristine Hunt at 978-671-1610.

Seahorse Bioscience, Inc.

Media Contact: Kristine Hunt

Phone: 978-671-1610


'/>"/>
SOURCE Seahorse Bioscience, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
4. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
5. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
9. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
10. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
11. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
(Date:6/23/2016)... India , June 23, 2016 ... media market research report to its pharmaceuticals section ... profiles, product details and much more. ... spread across 151 pages, profiling 15 companies and ... available at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . ...
Breaking Biology Technology:
(Date:6/27/2016)... June 27, 2016 Research and Markets has ... 2016-2020" report to their offering. ... America to grow at a CAGR of 12.28% during ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:6/22/2016)... , June 22, 2016  The American College of Medical ... Show Executive Magazine as one of the fastest-growing trade ... 25-27 at the Bellagio in Las Vegas ... highest percentage of growth in each of the following categories: ... companies and number of attendees. The 2015 ACMG Annual Meeting ...
(Date:6/22/2016)... 22, 2016   Acuant , the ... solutions, has partnered with RightCrowd ® ... Visitor Management, Self-Service Kiosks and Continuous Workforce ... add functional enhancements to existing physical access ... venues with an automated ID verification and ...
Breaking Biology News(10 mins):